Astal Lab

{
  "main_header": {
    "sid": 157295,
    "name": "Astal Lab",
    "stock_name": "Astal Lab",
    "full_name": "Astal Laboratories Ltd",
    "name_url": "stocks-analysis/astal-lab",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "86.50",
    "chg": 0.67,
    "chgp": "0.78%",
    "dir": 1,
    "prev_price": "85.83",
    "mcapval": "365.17 Cr",
    "mcap": "Micro Cap",
    "scripcode": 512600,
    "symbol": "",
    "ind_name": "Trading & Distributors",
    "ind_code": 49,
    "indexname": "",
    "isin": "INE307N01014",
    "curr_date": "Jan 19",
    "curr_time": "",
    "bse_nse_vol": "7.17 k",
    "exc_status": "Active",
    "traded_date": "Jan 19, 2026",
    "traded_date_str": "2026 01 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/astal-lab-157295-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Astal Laboratories Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-astal-laboratories-ltd-fallingrising-3790303",
        "imagepath": "",
        "date": "2026-01-13 00:59:06",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Outperformance Against Benchmarks and Sector</strong></p>\n<p>Astal Laboratories has outpaced the Sensex and its sector peers over the past week and month, with returns of +2.65% and +5.75% respectively, while the Sensex declined by 1.83% and 1.63% over the same periods. This divergence highlights the stock’s resilience amid a generally subdued market environment. Year-to-date, the stock has remained relatively flat with a marginal decline of 0.12%, outperforming the Sensex’s 1.58% fall. Over a longer horizon, Astal Laboratories has delivered exceptional returns, surging 207.08% over three years compared to the Sensex’s 39.89%, underscoring its strong growth trajectory.</p>\n<p><strong>Recent Price Action and Trading Dynamics</strong></p>\n<p>On 12-Jan, the stock touched an intraday high of ₹87..."
      },
      {
        "title": "Astal Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/astal-laboratories-ltd-is-rated-sell-3789752",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AstalLaboratori_mojoScore_3789752.png",
        "date": "2026-01-12 10:10:21",
        "description": "Astal Laboratories Ltd is rated 'Sell' by MarketsMOJO. This rating was last updated on 29 December 2025, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 12 January 2026, providing investors with the latest perspective on the company’s position."
      },
      {
        "title": "Astal Laboratories Downgraded to Sell Amid Mixed Financials and Technical Weakness",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/astal-laboratories-downgraded-to-sell-amid-mixed-financials-and-technical-weakness-3774173",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AstalLaboratori_mojoScore_3774173.png",
        "date": "2025-12-30 08:09:57",
        "description": "Astal Laboratories Ltd has seen its investment rating downgraded from Hold to Sell, driven primarily by a deterioration in technical indicators despite robust financial performance and attractive valuation metrics. The latest assessment by MarketsMOJO reflects a nuanced view of the company’s quality, valuation, financial trend, and technical outlook as of 29 Dec 2025."
      },
      {
        "title": "Astal Laboratories Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/astal-laboratories-ltd-is-rated-hold-3769677",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AstalLaboratori_mojoScore_3769677.png",
        "date": "2025-12-25 15:12:53",
        "description": "Astal Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 25 December 2025, providing investors with the most recent insights into its performance and outlook."
      },
      {
        "title": "Astal Lab’s Market Evaluation Revised Amidst Microcap Challenges",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/astal-lab-downgraded-to-sell-by-marketsmojo-amid-declining-mojo-score-3749798",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AstalLab_mojoScore_3749798.png",
        "date": "2025-12-06 10:10:33",
        "description": "Astal Lab, a microcap player in the Trading & Distributors sector, has experienced a revision in its market evaluation reflecting recent shifts in its fundamental and technical outlook. This adjustment comes amid a backdrop of subdued stock performance and evolving financial indicators."
      },
      {
        "title": "Is Astal Lab overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-astal-lab-overvalued-or-undervalued-3745256",
        "imagepath": "",
        "date": "2025-12-04 08:18:34",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Strong Valuation Metrics Highlight Undervaluation</strong></p>\n<p>Astal Lab’s price-to-earnings (PE) ratio stands at a modest 9.14, significantly lower than many of its peers in the trading and distribution space, where valuations often exceed 20 or even 100 times earnings. This low PE ratio suggests the market is pricing the stock conservatively relative to its earnings potential. Complementing this, the price-to-book value ratio of 2.07 indicates the stock is trading at just over twice its net asset value, a reasonable level for a company with strong returns on equity.</p>\n<p>The enterprise value to EBITDA ratio of 6.76 and EV to EBIT of 6.96 further reinforce the stock’s undervaluation. These multiples are well below those of several competitors, some of which trade at multiples exceeding..."
      },
      {
        "title": "How has been the historical performance of Astal Lab?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-astal-lab-3744702",
        "imagepath": "",
        "date": "2025-12-03 22:45:42",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue Growth and Operating Performance</strong></p>\n<p>Astal Lab's net sales have surged impressively from a modest ₹3.43 crores in the fiscal year ending March 2023 to ₹64.23 crores by March 2025. This exponential increase reflects the company's successful market penetration and scaling of operations. Total operating income mirrored this trend, rising from ₹3.43 crores to ₹64.23 crores over the same period, with no other operating income contributing to the top line.</p>\n<p>Raw material costs have understandably escalated in line with revenue growth, reaching ₹61.81 crores in March 2025 from zero reported in earlier years, indicating a shift from purchasing finished goods to in-house production. The company also reported a significant negative change in stocks, suggesting inventory build-..."
      },
      {
        "title": "Astal Laboratories Faces Cash Flow Challenges Despite Record Sales and Profitability",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/astal-laboratories-financial-trend-shifts-from-very-positive-to-positive-amid-cash-flow-challenges-3712011",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AstalLaboratori_fintrenddot_3712011.png",
        "date": "2025-11-18 14:00:10",
        "description": "Astal Laboratories reported record net sales of Rs 37.52 crore for the quarter ending September 2025, with a profit after tax of Rs 7.41 crore for the nine-month period. However, the company faces challenges with negative operating cash flow of Rs -12.52 crore, raising concerns about liquidity and operational efficiency."
      },
      {
        "title": "Astal Laboratories Q2 FY26: Explosive Growth Meets Margin Compression Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/astal-laboratories-q2-fy26-explosive-growth-meets-margin-compression-concerns-3718518",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AstalLaboratori_quaterlyResult_3718518.png",
        "date": "2025-11-18 12:33:48",
        "description": "Astal Laboratories Ltd., a micro-cap trading and distribution company with a market capitalisation of ₹96.00 crores, has delivered a quarter of remarkable top-line expansion tempered by margin compression concerns. In Q2 FY26, the company posted net profit of ₹2.58 crores, marking a 23.44% sequential increase from Q1 FY26's ₹2.09 crores and a robust 29.00% year-on-year growth from ₹2.00 crores in Q2 FY25. However, the stock has retreated 7.03% over the past week, trading at ₹88.80 as investors digest the margin dynamics beneath the headline numbers."
      }
    ],
    "total": 114,
    "sid": "157295",
    "stock_news_url": "https://www.marketsmojo.com/news/astal-laboratories-157295"
  },
  "announcements": [
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On 14Th January 2026",
      "datetime": "14-Jan-2026",
      "details": "Submission of outcome of board meeting.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Allotment",
      "datetime": "14-Jan-2026",
      "details": "Submission of intimation of allotment of equity shares.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Updates on Acquisition",
      "datetime": "14-Jan-2026",
      "details": "Submission of updates on Acquision.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Astal Laboratories Ltd falling/rising?

2026-01-13 00:59:06

Outperformance Against Benchmarks and Sector

Astal Laboratories has outpaced the Sensex and its sector peers over the past week and month, with returns of +2.65% and +5.75% respectively, while the Sensex declined by 1.83% and 1.63% over the same periods. This divergence highlights the stock’s resilience amid a generally subdued market environment. Year-to-date, the stock has remained relatively flat with a marginal decline of 0.12%, outperforming the Sensex’s 1.58% fall. Over a longer horizon, Astal Laboratories has delivered exceptional returns, surging 207.08% over three years compared to the Sensex’s 39.89%, underscoring its strong growth trajectory.

Recent Price Action and Trading Dynamics

On 12-Jan, the stock touched an intraday high of ₹87...

Read full news article

Astal Laboratories Ltd is Rated Sell

2026-01-12 10:10:21

Astal Laboratories Ltd is rated 'Sell' by MarketsMOJO. This rating was last updated on 29 December 2025, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 12 January 2026, providing investors with the latest perspective on the company’s position.

Read full news article

Astal Laboratories Downgraded to Sell Amid Mixed Financials and Technical Weakness

2025-12-30 08:09:57

Astal Laboratories Ltd has seen its investment rating downgraded from Hold to Sell, driven primarily by a deterioration in technical indicators despite robust financial performance and attractive valuation metrics. The latest assessment by MarketsMOJO reflects a nuanced view of the company’s quality, valuation, financial trend, and technical outlook as of 29 Dec 2025.

Read full news article

Astal Laboratories Ltd is Rated Hold

2025-12-25 15:12:53

Astal Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 25 December 2025, providing investors with the most recent insights into its performance and outlook.

Read full news article

Astal Lab’s Market Evaluation Revised Amidst Microcap Challenges

2025-12-06 10:10:33

Astal Lab, a microcap player in the Trading & Distributors sector, has experienced a revision in its market evaluation reflecting recent shifts in its fundamental and technical outlook. This adjustment comes amid a backdrop of subdued stock performance and evolving financial indicators.

Read full news article

Is Astal Lab overvalued or undervalued?

2025-12-04 08:18:34

Strong Valuation Metrics Highlight Undervaluation

Astal Lab’s price-to-earnings (PE) ratio stands at a modest 9.14, significantly lower than many of its peers in the trading and distribution space, where valuations often exceed 20 or even 100 times earnings. This low PE ratio suggests the market is pricing the stock conservatively relative to its earnings potential. Complementing this, the price-to-book value ratio of 2.07 indicates the stock is trading at just over twice its net asset value, a reasonable level for a company with strong returns on equity.

The enterprise value to EBITDA ratio of 6.76 and EV to EBIT of 6.96 further reinforce the stock’s undervaluation. These multiples are well below those of several competitors, some of which trade at multiples exceeding...

Read full news article

How has been the historical performance of Astal Lab?

2025-12-03 22:45:42

Revenue Growth and Operating Performance

Astal Lab's net sales have surged impressively from a modest ₹3.43 crores in the fiscal year ending March 2023 to ₹64.23 crores by March 2025. This exponential increase reflects the company's successful market penetration and scaling of operations. Total operating income mirrored this trend, rising from ₹3.43 crores to ₹64.23 crores over the same period, with no other operating income contributing to the top line.

Raw material costs have understandably escalated in line with revenue growth, reaching ₹61.81 crores in March 2025 from zero reported in earlier years, indicating a shift from purchasing finished goods to in-house production. The company also reported a significant negative change in stocks, suggesting inventory build-...

Read full news article

Astal Laboratories Faces Cash Flow Challenges Despite Record Sales and Profitability

2025-11-18 14:00:10

Astal Laboratories reported record net sales of Rs 37.52 crore for the quarter ending September 2025, with a profit after tax of Rs 7.41 crore for the nine-month period. However, the company faces challenges with negative operating cash flow of Rs -12.52 crore, raising concerns about liquidity and operational efficiency.

Read full news article

Astal Laboratories Q2 FY26: Explosive Growth Meets Margin Compression Concerns

2025-11-18 12:33:48

Astal Laboratories Ltd., a micro-cap trading and distribution company with a market capitalisation of ₹96.00 crores, has delivered a quarter of remarkable top-line expansion tempered by margin compression concerns. In Q2 FY26, the company posted net profit of ₹2.58 crores, marking a 23.44% sequential increase from Q1 FY26's ₹2.09 crores and a robust 29.00% year-on-year growth from ₹2.00 crores in Q2 FY25. However, the stock has retreated 7.03% over the past week, trading at ₹88.80 as investors digest the margin dynamics beneath the headline numbers.

Read full news article

View All News